GLYC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 12:10):

Stats
Today's Volume	275 754
Average Volume	453 709
Market Cap	110.53M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.150 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.96
ATR14	$0.00600 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Junius Daniel M	Buy	5 209	Common Stock
2024-03-29	King Rachel K.	Buy	3 334	Common Stock
2024-03-29	Goldberg Mark Alan	Buy	4 584	Common Stock
2024-01-12	Johnson Bruce S	Buy	250 000	Employee Stock Option (right to buy)
2024-01-12	Semerjian Harout	Buy	695 000	Employee Stock Option (right to buy)

INSIDER POWER
25.70
Last 98 transactions
Buy: 7 229 799 \| Sell: 5 299 394

Volume Correlation

Long: 0.18 (neutral)

Short: -0.67 (moderate negative)

Signal:(59.982) Neutral

GlycoMimetics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlycoMimetics Inc Correlation - Currency/Commodity

0.66
( moderate )

0.33
( neutral )

0.00
( neutral )

-0.24
( neutral )

0.00
( neutral )

0.58
( weak )

GlycoMimetics Inc Financials

Annual	2023
Revenue:	$10 000.00
Gross Profit:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

Q4	2023
Revenue:	$10 000.00
Gross Profit:	$-13 297.00 (-132.97 %)
EPS:	$-0.140

Q3	2023
Revenue:	$0
Gross Profit:	$-269 937 (0.00 %)
EPS:	$-0.140

Q2	2023
Revenue:	$0
Gross Profit:	$-265 866 (0.00 %)
EPS:	$-0.130

Financial Reports:

No articles found.

GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.